Virtual Library

Start Your Search

Keiji Miyoshi



Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-101 - A Retrospective Study of Lung Cancer that has Progressed to Brain Metastasis Alone (ID 14337)

      12:00 - 13:30  |  Author(s): Keiji Miyoshi

      • Abstract
      • Slides

      Background

      There is no consensus whether systemic therapy is needed after local treatment of lung cancer that has progressed to brain metastasis alone. To clarify the effect of treatment differences on patient survival, we conducted a retrospective study of treatment outcomes in patients with lung cancer that progressed to brain metastasis alone.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The study included patients diagnosed with lung cancer at our hospital between January 2011 and December 2016 and those with disease progression to brain metastasis alone by December 2017. We divided the patients according to the treatment administered and compared their characteristics and survival.

      4c3880bb027f159e801041b1021e88e8 Result

      This study included 26 patients. Among them, 7 patients were followed up after local treatment (FU) and 19 patients received systemic therapy after local treatment (ST). The patient characteristics were as follows: median age (years): FU, 71 and ST, 68; sex (male/female): FU, 5/2 and ST, 8/11; disease stage at diagnosis (I/II/III/IV/postoperative recurrence): FU, 3/0/3/1/0 and ST, 0/1/7/9/2; and histology (small cell lung cancer/non-small cell lung cancer): FU, 1/6 and ST, 6/13. There were no significant differences in survival between the two groups (median progression-free survival [PFS; months], FU vs. ST=9 vs. 5, P=0.581; median overall survival [months], FU vs. ST=26 vs. 13, P=0.656). Analysis of prognosis showed significant differences only in disease stage at diagnosis based on univariate Cox analysis of PFS (I–III vs. IV or postoperative recurrence; hazard ratio, 3.440; 95% confidence interval, 1.16-10.22; P=0.026).

      8eea62084ca7e541d918e823422bd82e Conclusion

      In patients with lung cancer that has progressed to brain metastasis alone, administration of systemic therapy may not be necessary until further disease progression after local treatment.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.